Efficacy and safety of sunitinib in patients with metastatic renal cell carcinoma on hemodialysis.

4646 Background: Sunitinib treatment is currently a standard of care for the treatment of metastatic renal cell carcinoma. Patients (pts) on hemodialysis however were excluded from studies and only few cases of pts on hemodialysis have been reported. Methods: We have performed a retrospective study by contacting over 100 hemodialysis institutions in Germany. 28 pts have been treated between November 2006 and July 2010. 21 pts, with a median age of 64 years (range 47-82) and a median ECOG of 1 (range 0-2) were evaluable. 16 pts had an intermediate risk, 2 pts a low risk and 3 pts a poor risk according to MKSCC criteria. Sunitinib doses applied were 25 mg (3 pts), 37.5 mg (8 pts) and 50 mg (9 pts) in the 4 week treatment and 2 weeks off schedule. 1 pat received 50 mg continuously. In median 9 courses were given (range 1–18). Results: The estimated median progression free survival of this cohort is 15 months (95% CI 11-19) and the median overall survival 29 months (95% CI 12-47). 1 of 21 pts (5%) reached a c...